Cargando…
Epigenetic Modification of Death Receptor Genes for TRAIL and TRAIL Resistance in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia
Immunotherapies specific for B-cell precursor acute lymphoblastic leukemia (BCP-ALL), such as anti-CD19 chimeric antigen receptor (CAR) T-cells and blinatumomab, have dramatically improved the therapeutic outcome in refractory cases. In the anti-leukemic activity of those immunotherapies, TNF-relate...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8229974/ https://www.ncbi.nlm.nih.gov/pubmed/34198757 http://dx.doi.org/10.3390/genes12060864 |
_version_ | 1783713097720004608 |
---|---|
author | Watanabe, Atsushi Miyake, Kunio Akahane, Koshi Goi, Kumiko Kagami, Keiko Yagita, Hideo Inukai, Takeshi |
author_facet | Watanabe, Atsushi Miyake, Kunio Akahane, Koshi Goi, Kumiko Kagami, Keiko Yagita, Hideo Inukai, Takeshi |
author_sort | Watanabe, Atsushi |
collection | PubMed |
description | Immunotherapies specific for B-cell precursor acute lymphoblastic leukemia (BCP-ALL), such as anti-CD19 chimeric antigen receptor (CAR) T-cells and blinatumomab, have dramatically improved the therapeutic outcome in refractory cases. In the anti-leukemic activity of those immunotherapies, TNF-related apoptosis-inducing ligand (TRAIL) on cytotoxic T-cells plays an essential role by inducing apoptosis of the target leukemia cells through its death receptors (DR4 and DR5). Since there are CpG islands in the promoter regions, hypermethylation of the DR4 and DR5 genes may be involved in resistance of leukemia cells to immunotherapies due to TRAIL-resistance. We analyzed the DR4 and DR5 methylation status in 32 BCP-ALL cell lines by sequencing their bisulfite PCR products with a next-generation sequencer. The DR4 and DR5 methylation status was significantly associated with the gene and cell-surface expression levels and the TRAIL-sensitivities. In the clinical samples at diagnosis (459 cases in the NOPHO study), both DR4 and DR5 genes were unmethylated in the majority of cases, whereas methylated in several cases with dic(9;20), MLL-rearrangement, and hypodiploidy, suggesting that evaluation of methylation status of the DR4 and DR5 genes might be clinically informative to predict efficacy of immunotherapy in certain cases with such unfavorable karyotypes. These observations provide an epigenetic rational for clinical efficacy of immunotherapy in the vast majority of BCP-ALL cases. |
format | Online Article Text |
id | pubmed-8229974 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-82299742021-06-26 Epigenetic Modification of Death Receptor Genes for TRAIL and TRAIL Resistance in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia Watanabe, Atsushi Miyake, Kunio Akahane, Koshi Goi, Kumiko Kagami, Keiko Yagita, Hideo Inukai, Takeshi Genes (Basel) Article Immunotherapies specific for B-cell precursor acute lymphoblastic leukemia (BCP-ALL), such as anti-CD19 chimeric antigen receptor (CAR) T-cells and blinatumomab, have dramatically improved the therapeutic outcome in refractory cases. In the anti-leukemic activity of those immunotherapies, TNF-related apoptosis-inducing ligand (TRAIL) on cytotoxic T-cells plays an essential role by inducing apoptosis of the target leukemia cells through its death receptors (DR4 and DR5). Since there are CpG islands in the promoter regions, hypermethylation of the DR4 and DR5 genes may be involved in resistance of leukemia cells to immunotherapies due to TRAIL-resistance. We analyzed the DR4 and DR5 methylation status in 32 BCP-ALL cell lines by sequencing their bisulfite PCR products with a next-generation sequencer. The DR4 and DR5 methylation status was significantly associated with the gene and cell-surface expression levels and the TRAIL-sensitivities. In the clinical samples at diagnosis (459 cases in the NOPHO study), both DR4 and DR5 genes were unmethylated in the majority of cases, whereas methylated in several cases with dic(9;20), MLL-rearrangement, and hypodiploidy, suggesting that evaluation of methylation status of the DR4 and DR5 genes might be clinically informative to predict efficacy of immunotherapy in certain cases with such unfavorable karyotypes. These observations provide an epigenetic rational for clinical efficacy of immunotherapy in the vast majority of BCP-ALL cases. MDPI 2021-06-05 /pmc/articles/PMC8229974/ /pubmed/34198757 http://dx.doi.org/10.3390/genes12060864 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Watanabe, Atsushi Miyake, Kunio Akahane, Koshi Goi, Kumiko Kagami, Keiko Yagita, Hideo Inukai, Takeshi Epigenetic Modification of Death Receptor Genes for TRAIL and TRAIL Resistance in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia |
title | Epigenetic Modification of Death Receptor Genes for TRAIL and TRAIL Resistance in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia |
title_full | Epigenetic Modification of Death Receptor Genes for TRAIL and TRAIL Resistance in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia |
title_fullStr | Epigenetic Modification of Death Receptor Genes for TRAIL and TRAIL Resistance in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia |
title_full_unstemmed | Epigenetic Modification of Death Receptor Genes for TRAIL and TRAIL Resistance in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia |
title_short | Epigenetic Modification of Death Receptor Genes for TRAIL and TRAIL Resistance in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia |
title_sort | epigenetic modification of death receptor genes for trail and trail resistance in childhood b-cell precursor acute lymphoblastic leukemia |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8229974/ https://www.ncbi.nlm.nih.gov/pubmed/34198757 http://dx.doi.org/10.3390/genes12060864 |
work_keys_str_mv | AT watanabeatsushi epigeneticmodificationofdeathreceptorgenesfortrailandtrailresistanceinchildhoodbcellprecursoracutelymphoblasticleukemia AT miyakekunio epigeneticmodificationofdeathreceptorgenesfortrailandtrailresistanceinchildhoodbcellprecursoracutelymphoblasticleukemia AT akahanekoshi epigeneticmodificationofdeathreceptorgenesfortrailandtrailresistanceinchildhoodbcellprecursoracutelymphoblasticleukemia AT goikumiko epigeneticmodificationofdeathreceptorgenesfortrailandtrailresistanceinchildhoodbcellprecursoracutelymphoblasticleukemia AT kagamikeiko epigeneticmodificationofdeathreceptorgenesfortrailandtrailresistanceinchildhoodbcellprecursoracutelymphoblasticleukemia AT yagitahideo epigeneticmodificationofdeathreceptorgenesfortrailandtrailresistanceinchildhoodbcellprecursoracutelymphoblasticleukemia AT inukaitakeshi epigeneticmodificationofdeathreceptorgenesfortrailandtrailresistanceinchildhoodbcellprecursoracutelymphoblasticleukemia |